References


  1. Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays 2004;26:21-28. 

  2. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int. 2008;73:1355-1363.
  3. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. BMJ 1988; 297:319-328.

  4. Woodhouse PR, Khaw KT, Plummer M. Seasonal variation of blood pressure and its relationship 
to ambient temperature in an elderly population. 
J Hypertens. 1993;11:1267-1274.

  5. Cooper R, Rotimi C. Hypertension in populations of West African origin: is there a genetic predisposition? J Hypertens. 1994;12:215-227.

  6. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997;30:150-156.

  7. Kunes J, Tremblay J, Bellavance F, Hamet P. Influence of environmental temperature on the blood pressure of hypertensive patients in Montreal. Am J Hypertens. 1991;4:422-426.

  8. Krause R, Buhring M, Hopfenmuller W et al. Ultraviolet B and blood pressure. Lancet 1998;352:709-710.

  9. Sowers MR, Wallace RB, Lemke JH. The association of intakes of vitamin D and calcium with blood pressure among women. Am J Clin Nutr. 1985;42:135-142.
  10. Jorde R, Bonaa KH. Calcium from dairy products, vitamin D intake, and blood pressure: the Tromso Study. Am J Clin Nutr. 2000;71:1530-1535.

  11. Forman JP, Bischoff-Ferrari HA, Willett WC et al. Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension 2005;46:676-682.

  12. Jacques PF, Sulsky SI, Sadowski JA et al. Comparison of micronutrient intake measured by a dietary questionnaire and biochemical indicators of micronutrient status. Am J Clin Nutr. 1993;57:182-189.

  13. Forman JP, Giovannucci E, Holmes MD et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49:1063-1069.

  14. Snijder MB, Lips P, Seidell JC et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med. 2007;261:558-565.

  15. Boucher BJ, Mannan N, Noonan K et al. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 1995;38:1239-1245.

  16. Baynes KC, Boucher BJ, Feskens EJ, Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997;40:344-347.

  17. Scragg R, Holdaway I, Singh V et al. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995;27:181-188.

  18. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2813-2818.

  19. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820-825.

  20. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980;209:823-825.

  21. Martins D, Wolf M, Pan D et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167:1159-1165.

  22. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005;28:1228-1230.

  23. Reis JP, von MD, Miller ER, III. Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur J Endocrinol. 2008;159:41-48.

  24. Dobnig H, Pilz S, Scharnagl H et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168:1340-1349.

  25. Pilz S, Marz W, Wellnitz B et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008;93:3927-3935.

  26. Pilz S, Dobnig H, Fischer JE et al. Low vitamin d levels predict stroke in patients referred to coronary angiography. Stroke 2008;39:2611-2613.

  27. Wang AY, Lam CW, Sanderson JE et al. Serum 25-
hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr. 2008;87:1631-1638.

  28. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629-1637.

  29. Mehrotra R, Kermah DA, Salusky IB et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009;76:977-983.

  30. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009;205:255-260.

  31. Melamed ML, Muntner P, Michos ED et al. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol. 2008;28:1179-1185.

  32. Chonchol M, Cigolini M, Targher G. Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. Nephrol Dial Transplant. 2008;23:269-274.

  33. de Boer IH, Kestenbaum B, Shoben AB et al. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20:1805-1812.

  34. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174-1180.

  35. Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin. 2008;24:139-149.

  36. Peterlik M, Cross HS. Dysfunction of the vitamin D endocrine system as common cause for multiple malignant and other chronic diseases. Anticancer Res. 2006; 26:2581-2588.

  37. Apperly FL. The relation of solar radiation to cancer mortality in North America. Cancer Res. 1941;1:191-195.

  38. Garland CF, Garland FC. Do sunlight and vitamin D 
reduce the likelihood of colon cancer? Int J 
Epidemiol. 1980;9:227-231.

  39. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med. 1990;19:614-622.

  40. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol. 1990;19:820-824.

  41. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-2869.

  42. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol. 1994;23:1133-1136.

  43. Giovannucci E, Liu Y, Rimm EB et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451-459.

  44. Pilz S, Dobnig H, Winklhofer-Roob B et al. Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients referred to coronary angiography. Cancer Epidemiol Biomarkers Prev. 2008;17:1228-1233.

  45. Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst. 2007;99:1594-1602.

  46. Garland CF, Comstock GW, Garland FC et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989;2:1176-1178.

  47. Skinner HG, Michaud DS, Giovannucci E et al. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev. 2006;15:1688-1695.

  48. Stolzenberg-Solomon RZ, Vieth R, Azad A et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res. 2006;66:10213-10219.

  49. Stolzenberg-Solomon RZ, Hayes RB, Horst RL et al. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res. 2009;69:1439-1447.

  50. Corder EH, Guess HA, Hulka BS et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993;2:467-472.

  51. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995;6:235-239.

  52. Gann PH, Ma J, Hennekens CH et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:121-126.

  53. Nomura AM, Stemmermann GN, Lee J et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9:425-432.

  54. Jacobs ET, Giuliano AR, Martinez ME et al. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol. 2004;89-90:533-537.

  55. Platz EA, Leitzmann MF, Hollis BW et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-265.

  56. Ahn J, Peters U, Albanes D et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008;100:796-804.

  57. Li H, Stampfer MJ, Hollis JB et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007;4:e103.

  58. Ingles SA, Ross RK, Yu MC et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997;89:166-170.

  59. Ma J, Stampfer MJ, Gann PH et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev. 1998;7:385-390.

  60. Xu Y, Shibata A, McNeal JE et al. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol
  61. Chen WY, Bertone-Johnson ER, Hunter DJ et al. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2335-2339.

  62. Mucci LA, Spiegelman D. Vitamin D and prostate cancer risk—a less sunny outlook? J Natl Cancer Inst. 2008;100:759-761.

  63. Feldman D, Zhao XY, Krishnan AV. Vitamin D and prostate cancer. Endocrinology 2000;141:5-9.

  64. Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol. 2009;19:84-88.

  65. Wactawski-Wende J, Kotchen JM, Anderson GL et al. Calcium plus vitamin D supplementation and the 
risk of colorectal cancer. N Engl J Med. 2006;354:
684-696.

  66. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167:1730-1737.



Continue Reading

HOW TO TAKE THE POST-TEST: To obtain CME credit, please click here after reading the article to take the post-test on myCME.com.